User:Jimposada/sandbox

RSLV-132 is a biologic drug being developed by Resolve Therapeutics for the treatment of autoimmune diseases such as systemic lupus erythematosus and Sjogren's Syndrome. The drug is in a class of proteins known as fusion proteins and comprised of catalytically active RNase fused to the Fc domain of human immunoglobulin (IgG1).